Recent upward revisions to earnings estimates for AtaiBeckley (ATAI) have helped draw fresh attention to the stock, as a broad analyst consensus on improved financial expectations aligns with strong recent share price momentum.

The recent 40.23% 1 month share price return and 79.90% 3 month share price return for AtaiBeckley, alongside a 331.55% 3 year total shareholder return but a 46.77% decline over five years, points to strong but relatively recent momentum as investors reassess the company after the latest earnings estimate revisions.

If AtaiBeckley’s recent move has you rethinking your watchlist, this could be a good moment to look at other opportunities using our screener of 42 healthcare AI stocks.

The recent surge puts AtaiBeckley at a meaningful discount to the US$9.59 average analyst target. The market is still pricing in caution after years of mixed returns, so investors may be wondering whether that gap signals an opportunity or a lingering risk mispricing.

Preferred Price-to-Book Multiple of 13.5x: Is It Justified?

AtaiBeckley last closed at $7.25, and the stock trades on a P/B of 13.5x compared with 2.6x for the broader US pharmaceuticals industry and 7.8x for its peer group. That gap suggests the market is putting a much richer value on AtaiBeckley’s equity base than on many comparable companies.

The P/B ratio compares a company’s share price to its book value per share, which is essentially net assets on the balance sheet. For a clinical stage biopharmaceutical company like AtaiBeckley, a high P/B often reflects investor focus on the potential value of the pipeline and future revenue streams rather than current earnings or asset intensity.

AtaiBeckley is currently unprofitable, with losses having increased over the past five years and no profitability expected over the next three years. In that context, a 13.5x P/B suggests the market is already baking in meaningful future progress on its mental health treatment portfolio, even though revenue is not yet at a meaningful level and the company reports that 100% of its liabilities come from higher risk external borrowing.

Compared with the US pharmaceuticals industry average P/B of 2.6x and a peer average of 7.8x, AtaiBeckley’s 13.5x multiple stands out as significantly more expensive. The market is assigning a substantial premium to the stock relative to both the wider industry and closer peers, so any change in sentiment around its clinical programs or funding profile could have an outsized impact on the valuation.

Result: Price-to-book of 13.5x (OVERVALUED)

However, AtaiBeckley still faces clinical trial uncertainty and ongoing losses of $663.398m, which together could quickly shift sentiment on the current premium valuation.

Next Steps

All of this leaves a mixed picture around AtaiBeckley, with clear risks and some potential rewards in play. If you want to move quickly and form your own view based on the underlying data, take a closer look at the 1 key reward and 4 important warning signs.

Looking for more investment ideas beyond AtaiBeckley?

If AtaiBeckley is already on your radar, do not stop there. Use the tools available to compare it with other possibilities and sharpen your next move.

• Spot potential bargains early by scanning companies that trade below what their fundamentals might support with the help of 49 high quality undervalued stocks.
• Strengthen your portfolio’s foundation by focusing on companies with healthier finances through the solid balance sheet and fundamentals stocks screener (49 results).
• Seek out less crowded opportunities by reviewing the screener containing 19 high quality undiscovered gems before others catch on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.